[SCHEDULE 13G] IGM Biosciences, Inc. SEC Filing

Rhea-AI Filing Summary

Glazer Capital, LLC and its Managing Member Paul J. Glazer have filed a Schedule 13G disclosing beneficial ownership of 2,534,803 shares of IGM Biosciences, Inc. (NASDAQ: IGMS) common stock. The position represents 7.30 % of the outstanding shares as of the 07 July 2025 filing date (event date 02 July 2025), crossing the 5 % threshold that requires public reporting under Section 13 of the Securities Exchange Act.

The filing indicates shared voting and dispositive power over the entire position; neither Glazer Capital nor Mr. Glazer holds sole voting or dispositive authority. The shares are held by “Glazer Funds” – investment funds and managed accounts advised by Glazer Capital – suggesting the stake is part of an investment strategy rather than an attempt to influence control, as affirmed in the certification section.

Given IGMS’s market capitalization and trading volumes, a 7.3 % holding is material and signals increased institutional interest. However, the document contains no information on purchase price, investment thesis, or future intentions beyond passive ownership. Investors may monitor subsequent filings for changes in ownership or a shift from Schedule 13G (passive) to Schedule 13D (active) to gauge potential strategic actions.

Positive

• Institutional ownership increases: Glazer Capital now holds 7.3 % of IGMS, potentially improving liquidity and investor visibility.

Negative

• None.

Insights

Portfolio Manager

TL;DR 7.3 % passive stake by Glazer Capital signals institutional interest; no activist intent stated.

The 13G shows Glazer Capital controls 2.53 M IGMS shares, a meaningful but minority position. Because the filing is a 13G, the fund certifies it is a passive holder, reducing near-term risk of activist campaigns. Still, a sophisticated event-driven manager taking a >5 % stake can improve market liquidity and serve as a vote of confidence in IGMS’s pipeline prospects. Impact is moderately positive for sentiment but does not change fundamentals. Watch subsequent amendments: a move above 10 % or conversion to 13D would become significantly more impactful.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

IGM Biosciences, Inc.

(Name of Issuer)

Common Stock, par value $0.01 per share

(Title of Class of Securities)

449585108

(CUSIP Number)

07/02/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 449585108

1

Names of Reporting Persons

Glazer Capital, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,534,803.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,534,803.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,534,803.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.30 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. 449585108

1

Names of Reporting Persons

Paul J. Glazer

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,534,803.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,534,803.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,534,803.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.30 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: IGM Biosciences, Inc.
(b)	Address of issuer's principal executive offices: 325 E Middlefield Road, Mountain View, CA, 94043
Item 2.
(a)	Name of person filing: This statement is filed by: (i) Glazer Capital, LLC, a Delaware limited liability company ("Glazer Capital"), with respect to the shares of Common Stock (as defined in Item 2(d)) held by certain funds and managed accounts to which Glazer Capital serves as investment manager (collectively, the "Glazer Funds"); and (ii) Mr. Paul J. Glazer ("Mr. Glazer"), who serves as the Managing Member of Glazer Capital, with respect to the shares of Common Stock held by the Glazer Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock (as defined in Item 2(d)) reported herein.
(b)	Address or principal business office or, if none, residence: The address of the business office of each of the Reporting Persons is 250 West 55th Street, Suite 30A, New York, New York 10019.
(c)	Citizenship: Glazer Capital is a Delaware limited liability company. Mr. Glazer is a United States citizen.
(d)	Title of class of securities: Common Stock, par value $0.01 per share
(e)	CUSIP No.: 449585108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 2,534,803
(b)	Percent of class: 7.30%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 2,534,803
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 2,534,803
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Glazer Capital, LLC

Signature:	Paul J. Glazer
Name/Title:	Paul J. Glazer, Managing Member
Date:	07/09/2025

Paul J. Glazer

Signature:	Paul J. Glazer
Name/Title:	Paul J. Glazer
Date:	07/09/2025

FAQ

How many IGMS shares does Glazer Capital now own?

2,534,803 common shares, representing 7.30 % of the outstanding class.

Is Glazer Capital acting as an activist in IGMS?

The Schedule 13G filing classifies the position as passive; no activist intent is disclosed.

What voting power does Glazer Capital have over the IGMS shares?

The fund reports shared voting and dispositive power over all 2.53 M shares; it has no sole authority.

When was the ownership threshold that triggered this filing crossed?

The event date is 07/02/2025, prompting the Schedule 13G disclosure.

Who is Paul J. Glazer in relation to the IGMS stake?

Mr. Glazer is the Managing Member of Glazer Capital, LLC and a joint reporting person on the filing.

Does the filing reveal the purchase price of the shares?

No pricing or cost basis information is provided in the Schedule 13G.